RPG Life Sciences Ltd
RPG Life Sciences Ltd (RPGLIFE) last reported results for the quarter ended Jun 2026, with sales of ₹196 crore and net profit of ₹31 crore. The stock last traded at ₹2,927, a market capitalisation of ₹4,841 crore, on a P/E of 41.4. Over the past 52 weeks the stock has ranged between ₹1,731 and ₹3,130. Figures are as of 6 Oct 2026 and are not real time.
RPG Life Sciences Ltd share price and key metrics
- Current price
- ₹2,927
- Market cap
- ₹4,841 cr
- Stock P/E
- 41.4
- Book value
- ₹366
- ROE
- 19.3%
- ROCE
- 25.7%
- Dividend yield
- 0.83%
- 52w high / low
- 3130/1731
Metrics as of 6 Oct 2026. Not real time.
Track RPG Life Sciences Ltd
Cruxal reads every RPG Life Sciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
RPG Life Sciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 8%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -5%
- 10 Years
- 20%
- 5 Years
- 33%
- 3 Years
- 32%
- 1 Year
- 29%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 19%
RPG Life Sciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹196 cr, up 16.0% from ₹169 cr a year earlier. Net profit was ₹31 cr, up 19.2% year on year.
| ₹ crore | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|
| Sales | 173 | 143 | 169 | 182 | 180 | 177 | 196 |
| Expenses | 124 | 118 | 133 | 143 | 140 | 144 | 152 |
| Operating profit | 49 | 25 | 35 | 39 | 40 | 33 | 43 |
| OPM % | 28% | 18% | 21% | 21% | 22% | 19% | 22% |
| Other income | 3 | 115 | 5 | 16 | -5 | 14 | 5 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 5 | 5 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 47 | 135 | 35 | 49 | 29 | 40 | 41 |
| Tax % | 26% | 13% | 26% | 25% | 24% | 26% | 26% |
| Net profit | 35 | 117 | 26 | 37 | 22 | 30 | 31 |
| EPS (₹) | 21.12 | 70.95 | 15.90 | 22.28 | 13.38 | 18.08 | 18.60 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
RPG Life Sciences Ltd annual results
| ₹ crore | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|
| Sales | 653 | 708 | 734 |
| Operating profit | 161 | 148 | 155 |
| OPM % | 25% | 21% | 21% |
| Net profit | 183 | 115 | 120 |
| EPS (₹) | 110.79 | 69.64 | 72.34 |
TTM is the trailing twelve months to the most recent quarter.
RPG Life Sciences Ltd balance sheet
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Equity capital | 13 | 13 |
| Reserves | 517 | 592 |
| Borrowings | 0 | 20 |
| Other liabilities | 127 | 168 |
| Total liabilities | 658 | 793 |
| Fixed assets | 172 | 197 |
| CWIP | 16 | 23 |
| Investments | 127 | 85 |
| Other assets | 343 | 488 |
| Total assets | 658 | 793 |
As reported by the company. Total assets equal total liabilities by construction.
RPG Life Sciences Ltd cash flow
| ₹ crore | Mar 2025 | Mar 2026 |
|---|---|---|
| Cash from operations | 78 | 56 |
| Cash from investing | -42 | 86 |
| Cash from financing | -27 | -21 |
| Net cash flow | 9 | 122 |
| Free cash flow | 151 | -9 |
| CFO / operating profit | 81% | 63% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
RPG Life Sciences Ltd operating ratios
| Per year | Mar 2025 | Mar 2026 |
|---|---|---|
| ROCE % | — | 26% |
| Debtor days | 48 | 60 |
| Inventory days | 159 | 179 |
| Days payable | 135 | 141 |
| Cash conversion cycle | 72 | 99 |
| Working capital days | 45 | 64 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
RPG Life Sciences Ltd shareholding pattern
Promoters held 72.95% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.95% and DIIs 8.68%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 72.82% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% | 72.95% |
| FIIs | 1.35% | 1.30% | 1.46% | 1.35% | 1.11% | 1.00% | 0.87% | 0.95% |
| DIIs | 5.45% | 6.06% | 6.14% | 6.49% | 6.70% | 7.04% | 7.45% | 8.68% |
| Public | 20.40% | 19.70% | 19.46% | 19.22% | 19.23% | 19.01% | 18.72% | 17.42% |
| No. of shareholders | 23,481 | 24,891 | 24,867 | 25,832 | 26,657 | 25,905 | 25,282 | 23,886 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
RPG Life Sciences Ltd corporate filings
- Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018Company Updatelow impact
- RPG Life Sciences publishes newspaper advertisement regarding special window for transfer and dematerialization requestsCompany Updatelow impact
Cruxal's analysis: The company announced a newspaper publication related to a designated window for lodging…
Read the full analysis - ChrysCapital Increases Stake in RPG Life Sciences Limited to 7.04% via Open Market PurchaseInsider Trading / SASTmedium impact
Cruxal's analysis: ChrysCapital, through its Clarus Trust schemes, has increased its shareholding in RPG…
Read the full analysis - RPG Life Sciences announces internal restructuring via amalgamation of subsidiary Actis Generics with RPG Active PharmaCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has disclosed that its subsidiary, RPG Active Pharma Limited, will…
Read the full analysis - Closure of Trading WindowInsider Trading / SASTlow impact
- RPG Life Sciences provides update on Share Purchase Agreement with Actis Generics Private LimitedCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has issued a status update regarding the Share Purchase Agreement…
Read the full analysis - RPG Life Sciences clarifies on recent stock volume movementCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has issued a clarification regarding the recent increase in trading…
Read the full analysis - RPG Life Sciences schedules analyst and institutional investor meetingCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has issued an intimation regarding a scheduled meeting with analysts…
Read the full analysis - RPG Active Pharma Limited completes Business Transfer Agreement with Raghava Life Sciences Private LimitedCompany Updatelow impact
Cruxal's analysis: RPG Active Pharma Limited, a subsidiary of RPG Life Sciences, has finalized the execution…
Read the full analysis - RPG Life Sciences subsidiary completes securities allotment following July 29, 2026 Shareholders AgreementCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has confirmed the completion of a securities allotment by its…
Read the full analysis - RPG Life Sciences reports outcome of analyst/institutional investor meetingCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences held a meeting with analysts and institutional investors on September…
Read the full analysis - RPG Life Sciences Ltd schedules investor meet for September 3, 2026Company Updatelow impact
Cruxal's analysis: RPG Life Sciences has issued an intimation regarding an investor meet scheduled for…
Read the full analysis - RPG Life Sciences Announces Strategic Restructuring and Expansion of API Business via RPGAP SubsidiaryCompany Updatehigh impact
Cruxal's analysis: RPG Life Sciences has initiated a significant strategic restructuring by transferring its…
Read the full analysis - RPG Life Sciences announces schedule for investor meetingCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has issued an intimation regarding a scheduled investor meeting to be…
Read the full analysis - RPG Life Sciences Ltd files routine press release under Regulation 30Company Updatelow impact
Cruxal's analysis: RPG Life Sciences has submitted a press release under Regulation 30 of the SEBI (LODR)…
Read the full analysis - RPG Life Sciences to acquire API and Intermediates business of Raghava Life Sciences for INR 135 croreCompany Updatehigh impact
Cruxal's analysis: RPG Life Sciences, through its wholly owned subsidiary RPG Active Pharma Limited, has…
Read the full analysis - RPG Life Sciences Ltd announces cancellation of scheduled investor meetCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has formally notified the exchange regarding the cancellation of a…
Read the full analysis - RPG Life Sciences schedules analyst and institutional investor meetingCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has announced a scheduled meeting with analysts and institutional…
Read the full analysis - RPG Life Sciences schedules analyst and institutional investor meetingCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences has announced a scheduled meeting with analysts and institutional…
Read the full analysis - RPG Life Sciences announces internal leadership transition for API businessCompany Updatelow impact
Cruxal's analysis: RPG Life Sciences Limited has announced that Mr. Deepak Shukla has resigned as Chief…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.